Ovid Therapeutics (OVID) Total Liabilities (2016 - 2026)

Ovid Therapeutics (OVID) has reported Total Liabilities for 11 consecutive years, with $22.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 2.05% year-over-year to $22.1 million; the trailing twelve-month figure through Jun 2026 stood at $22.1 million (up 2.05% YoY), and the FY2025 full-year result was $20.3 million, down 15.32% from the prior year.
• Total Liabilities fell to $22.1 million in Q2 2026 per OVID's latest filing, from $27.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $56.2 million in Q4 2023 and bottomed at $19.2 million in Q3 2025.
• Historically, Total Liabilities has averaged $27.3 million across 5 years, with a median of $23.8 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities soared 144.55% in 2023, then plunged 58.04% in 2025.
• Over 5 years, Total Liabilities stood at $23.0 million in 2022, then jumped by 144.55% to $56.2 million in 2023, then plunged by 57.42% to $23.9 million in 2024, then slipped by 15.32% to $20.3 million in 2025, then grew by 8.92% to $22.1 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $22.1 million, $27.4 million, and $20.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.